Eloxx Pharmaceuticals (OTCPK:ELOX) - 주가, 뉴스 및 분석

ELOX 주식 개요

임상 단계의 바이오 제약 회사인 엘록스 파마슈티컬스는 희귀 및 극희귀 조기 중단 코돈 질환 치료를 위한 리보솜 조절 개발에 주력하고 있습니다. 자세한 내용

ELOX 기본 분석
눈송이 점수
가치 평가	2/6
미래 성장	0/6
과거 실적	0/6
재무 상태	0/6
배당금	0/6

위험 분석

수익이 1백만 달러 미만인 경우 ( $0 )

의미 있는 시가총액이 없습니다. ( $3 )

최근 3개월간 주가 변동폭 심해

마이너스 주주 지분

+ 2 더 많은 위험

Eloxx Pharmaceuticals, Inc. 경쟁사

Plant-Based Investment

OTCPK:CWWB.F

US$27.0

PLx Pharma Winddown

OTCPK:PLXP.Q

US$30.0

MJ Holdings

OTCPK:MJNE

US$58.0

RVL Pharmaceuticals

OTCPK:RVLP.Q

US$111.0

가격 내역 및 성능

다음에 대한 모든 사상 최고가, 변동 및 가격 하락 요약 Eloxx Pharmaceuticals
과거 주가
현재 주가	US$0.000001
52주 최고치	US$1.74
52주 최저치	US$0.000001
베타	-24.6
11개월 변경	-99.50%
3개월 변경 사항	0%
1년 변경 사항	-100.00%
33년 변화	-100.00%
5년 변화	-100.00%
IPO 이후 변화	-100.00%

최근 뉴스 및 업데이트

Recent updates

Eloxx secures additional funding from CF Foundation for ELX-02 mid-stage study in cystic fibrosis

Jan 13

주주 수익률

	ELOX	US Pharmaceuticals	US 마켓
7D	-99.0%	3.4%	1.6%
1Y	-100.0%	14.2%	32.3%

수익률 대 산업: ELOX 지난 1년 동안 14.2 %를 반환한 US Pharmaceuticals 업계보다 저조한 성과를 냈습니다.

수익률 대 시장: ELOX 지난 1년 동안 32.3 %를 반환한 US 시장보다 저조한 성과를 냈습니다.

가격 변동성

Is ELOX's price volatile compared to industry and market?
ELOX volatility
ELOX Average Weekly Movement	23,019.7%
Pharmaceuticals Industry Average Movement	10.0%
Market Average Movement	6.3%
10% most volatile stocks in US Market	16.2%
10% least volatile stocks in US Market	3.1%

안정적인 주가: ELOX 의 주가는 지난 3개월 동안 변동성이 심했습니다.

시간에 따른 변동성: ELOX 의 주간 변동성은 지난 1년 동안 9910% 에서 23020% 로 증가했습니다.

회사 소개

설립	직원	CEO	웹사이트
2013	18	Sumit Aggarwal	www.eloxxpharma.com

임상 단계의 바이오 제약 회사인 엘록스 파마슈티컬스는 희귀 및 극희귀 조기 중단 코돈 질환 치료를 위한 리보솜 조절 개발에 주력하고 있습니다. 주요 임상시험용 의약품 후보물질은 넌센스 돌연변이가 진단된 낭포성 섬유증 및 신병증성 시스틴증 환자 치료를 위한 임상 2상 시험 중인 ELX-02입니다. 또한 알포트 증후군, 열성 영양 장애성 수포성 표피 박리증, 접합성 표피 박리증, 가족성 선종성 용종증 치료를 위한 다양한 전임상 프로그램과 종양학 분야의 다양한 초기 발견 단계 프로그램도 개발하고 있습니다.

Eloxx Pharmaceuticals, Inc. 기본 사항 요약

Eloxx Pharmaceuticals 의 수익과 매출은 시가총액과 어떻게 비교하나요?
ELOX 기본 통계
시가총액	US$3.00
수익(TTM)	-US$20.48m
수익(TTM)	n/a

0.0x

P/S 비율

0.0x

P/E 비율

ELOX 주가가 과대평가되어 있나요?

공정 가치 및 가치 분석 보기

수익 및 수익

최신 수익 보고서의 주요 수익성 통계(TTM)
ELOX 손익 계산서(TTM)
수익	US$0
수익 비용	US$0
총 이익	US$0
기타 비용	US$20.48m
수익	-US$20.48m

최근 보고된 수익

Sep 30, 2023

다음 수익 날짜

n/a

주당 순이익(EPS)	-6.21
총 마진	0.00%
순이익 마진	0.00%
부채/자본 비율	-91.8%

ELOX 의 장기적인 성과는 어땠나요?

과거 실적 및 비교 보기

ELOX 주식 개요

위험 분석

Eloxx Pharmaceuticals, Inc. 경쟁사

OTCPK:CWWB.F

US$27.0

OTCPK:PLXP.Q

US$30.0

OTCPK:MJNE

US$58.0

OTCPK:RVLP.Q

US$111.0

가격 내역 및 성능

최근 뉴스 및 업데이트

Eloxx Pharmaceuticals, Inc. announced delayed 10-Q filing

Eloxx Pharmaceuticals Announces Key Corporate Accomplishments

Eloxx Pharmaceuticals, Inc. announced delayed 10-Q filing

Eloxx Pharmaceuticals, Inc. announced that it expects to receive $3.175 million in funding

Eloxx Pharmaceuticals, Inc. announced delayed 10-Q filing

Eloxx Pharmaceuticals, Inc. announced delayed annual 10-K filing

Recent updates

Eloxx Pharmaceuticals, Inc. announced delayed 10-Q filing

Eloxx Pharmaceuticals Announces Key Corporate Accomplishments

Eloxx Pharmaceuticals, Inc. announced delayed 10-Q filing

Eloxx Pharmaceuticals, Inc. announced that it expects to receive $3.175 million in funding

Eloxx Pharmaceuticals, Inc. announced delayed 10-Q filing

Eloxx Pharmaceuticals, Inc. announced delayed annual 10-K filing

Nasdaq to Delist Common Stock of Eloxx Pharmaceuticals

Eloxx Pharmaceuticals, Inc. Announces Resignation of Tomer Kariv from the Board

Eloxx Pharmaceuticals Receives a Determination Letter from the Staff of the Listing Qualifications Department of the Nasdaq Stock Market

Eloxx Pharmaceuticals, Inc. Announces Resignation of Vijay Modur as Head of Research and Development

Eloxx Pharmaceuticals, Inc. Provides Updates on ELX-02 and ZKN-013

New minor risk - Shareholder dilution

Eloxx Pharmaceuticals, Inc. Reports Drug Response in All Patients Treated with ELX-02 in Phase 2 Clinical Study for Alport Syndrome

Nasdaq Grants Extension to Eloxx Pharmaceuticals to Regain Compliance with the Market Value of Listed Securities Continued Listing Requirement

New major risk - Market cap size

Eloxx Pharmaceuticals, Inc. Announces Final Data Assessment from Phase 2 Combination Clinical Trial of ELX-02 in Class 1 Cystic Fibrosis (CF) Patients

Eloxx Pharmaceuticals Receives Extension by Nasdaq to Regain Compliance with the Market Value of Listed Securities Continued Listing Requirement

Eloxx Pharmaceuticals, Inc. Announces First Patients Enrolled in Phase 2 Clinical Study Evaluating Elx-02 for the Treatment of Alport Syndrome

Price target increased to US$3.00

Eloxx Pharmaceuticals, Inc. Announces Opening of Clinical Trial Sites for Phase 2 Study of ELX-02 for the Treatment of Alport Syndrome

Eloxx Pharmaceuticals Receives Written Notification Letter from the Listing Qualifications Department of Nasdaq

Eloxx Pharmaceuticals, Inc. Announces Topline Results from the Phase 2 Clinical Trial of ELX-02 in Combination with Ivacaftor in Class 1 Cystic Fibrosis (CF) Patients with At Least One Nonsense Mutation

Eloxx says lead asset failed in mid-stage cystic fibrosis trial

Eloxx Pharmaceuticals GAAP EPS of -$0.12 in-line

Eloxx Pharmaceuticals, Inc. Announces Committee Changes

Price target decreased to US$2.25

Eloxx Pharmaceuticals, Inc., Annual General Meeting, Jun 15, 2022

Price target decreased to US$3.00

Eloxx Pharmaceuticals, Inc. Announces New Development Program for ELX-02 for the Treatment of Alport Syndrome

Price target decreased to US$3.00

Eloxx Pharmaceuticals Receives A Letter from the Listing Qualifications Department of the Nasdaq Stock Market

President exercised options and sold US$59k worth of stock

Price target increased to US$4.03

Is Eloxx Pharmaceuticals (NASDAQ:ELOX) Using Debt In A Risky Way?

COO, General Counsel & Corporate Secretary Neil Belloff has left the company

Executive Director of Finance & Accounting, Corporate Controller and Treasurer Gary Rakers has left the company

Eloxx Pharmaceuticals, Inc.(NasdaqGM:ELOX) dropped from Russell 3000E Index

Eloxx Pharmaceuticals, Inc. has completed a Follow-on Equity Offering in the amount of $45.000001 million.

Eloxx Pharmaceuticals EPS misses by $0.06

Independent Director has left the company

CEO & Director Gregory Williams has left the company

Founder & Director Silvia Noiman has left the company

VP of Finance & Accounting, Principal Financial & Accounting Officer and Treasurer has left the company

Eloxx Pharmaceuticals, Inc. Announces Resignation of Stephen Macdonald as Vice President, Finance and Accounting, and Treasurer (Principal Financial and Accounting Officer) Effective March 26, 2021

Eloxx Pharmaceuticals, Inc. to Report Q4, 2020 Results on Mar 11, 2021

CEO & Director exercised options and sold US$61k worth of stock

New 90-day high: US$4.51

What Kind Of Investors Own Most Of Eloxx Pharmaceuticals, Inc. (NASDAQ:ELOX)?

The Cystic Fibrosis Foundation Awards upto $2 Million to Eloxx Pharmaceuticals Inc. for Additional Support of Phase 2 Clinical Studies of Potential Therapy for Nonsense Mutations

Eloxx secures additional funding from CF Foundation for ELX-02 mid-stage study in cystic fibrosis

New 90-day high: US$3.94

New 90-day low: US$2.42

Eloxx Pharmaceuticals, Inc. to Report Q3, 2020 Results on Nov 05, 2020

New 90-day low: US$2.68

Eloxx Pharmaceuticals, Inc. to Report Q2, 2020 Results on Aug 06, 2020

Eloxx Pharmaceuticals, Inc.(NasdaqGM:ELOX) dropped from Russell Microcap Value Index

주주 수익률

가격 변동성

회사 소개

Eloxx Pharmaceuticals, Inc. 기본 사항 요약